Pharmaceutical Companies. Pharma companies are utilizing AI to accelerate the time-consuming—and expensive—drug discovery process. Traditionally, it takes pharmaceutical companies an average of 10 years and $3 billion to bring a drug to market.

Where it’s headed next: For one, the nimble startup snapped up biosensor maker Biovotion last year—and this April, it acquired Gaido Health from Takeda pharmaceuticals to wade into the oncology space. It also just bagged $100 million in Series C funding this September to expand its portfolio of offerings, which it could use to broaden its presence in Asian markets.

For example, last November, Janssen Pharmaceuticals teamed up with DTx provider Koa Health to research the effectiveness of deploying mental health DTx for major depressive disorder. And Boehringer Ingelheim inked a $500 million deal with DTx vendor Click Therapeutics to develop and commercialize a digital treatment for schizophrenic patients.

The $780 billion pharmaceuticals market is attracting tech firms that have been digging into segments across the healthcare continuum: Alphabet boasts its own life sciences arm, Verily, which is involved in projects—like its Project Baseline—that are amassing troves of data that could eventually help make care and treatments more precise and effective.

The third bucket of money is the pharmaceutical benefit. There are several digital therapy companies that have tried to get access to that bucket of money—it's a big bucket. And what [digital therapeutics companies] do is clearly therapy, but we're not a pharmaceutical product.

Pharmaceutical companies are also vulnerable. Cybercriminals have targeted pharma and biotech firms to gain access to COVID-19 research and vaccine development data, according to Reposify’s 2021 report titled “Pharmaceutical Industry: The State of the External Attack Surface.” Some 92% of pharmaceutical companies had at least one exposed database with potential data leakage, the report noted.

Healthcare and pharma: Includes pharmaceutical products, facilities, services, researchers, drug manufacturers and marketers, doctors, hospitals, and biological products, as well as establishments providing healthcare services and social assistance for individuals; also includes health insurance.

For example, last November, DTx vendor Koa teamed up with Johnson & Johnson’s Janssen Pharmaceuticals to research the delivery of digital CBT to treat treatment-resistant major depressive disorder. And in February of this year, Click Therapeutics partnered with Otsuka to evaluate the effectiveness of its DTx in reducing depressive symptoms in adults with MDD. What's next?

We define healthcare and pharma to include pharmaceutical products, facilities, services, researchers, drug manufacturers and marketers, doctors, hospitals, and biological products. It also includes establishments providing healthcare services and social assistance for individuals, as well as health insurance advertising.

Healthcare and pharma: Includes pharmaceutical products, facilities, services, researchers, drug manufacturers and marketers, doctors, hospitals, and biological products, as well as establishments providing healthcare services and social assistance for individuals; also includes health insurance.